Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes. Its ENHANZE® drug delivery technology, powered by the proprietary enzyme rHuPH20, enables rapid subcutaneous delivery of injected drugs and fluids, reducing treatment burden. ENHANZE® is used in ten commercialized products across 100+ global markets and licensed to leading pharmaceutical and biotechnology companies. Halozyme also develops, manufactures, and commercializes drug-device combination products, including Hylenex® and XYOSTED®, and partners on programs to enhance convenience, reliability, and patient adherence. Learn more at www.halozyme.com and connect with us on LinkedIn and Twitter.